<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173717</url>
  </required_header>
  <id_info>
    <org_study_id>1160.100</org_study_id>
    <nct_id>NCT02173717</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule)When Administered Alone, After Seven Days of Dosing With 600 mg Rifampicin(Tablet), and Seven Days and Fourteen Days After Last Administration of Rifampicin in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate whether and to what extent the suggested P-glycoprotein (P-gp) inducer
      rifampicin affects plasma exposure of dabigatran.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-inf) of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration (Cmax) of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 334hours after treatment on Day1, 9, 16 and 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of dabigatran etexilate</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration (tmax) of dabigatran etexilate</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of BIBR 1087SE</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of BIBR 1087SE</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of BIBR 951BS</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of BIBR 951BS</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve over the time interval from timepoints t1 to t2 (AUCt1-t2) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve over the time interval from 0 to 24 h (AUC0-24) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant (λz) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after oral administration (MRTpo) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance after extravascular administration (CL/F) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) of free dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of total dabigatran</measure>
    <time_frame>30 min pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 34 hours after treatment on Day1, 9, 16 and 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount that is eliminated in urine from the time interval 0- 24h (Ae0-24) of total dabigatran</measure>
    <time_frame>Day 1 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction excreted unchanged in urine from time point 0-24h (fe0-24) of total dabigatran</measure>
    <time_frame>Day 1 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance from the time point 0 until the point 0-24h (CLR, 0-24) of total dabigatran</measure>
    <time_frame>Day 1 and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 6-ß-hydroxycortisol/cortisol in morning spot urine as a marker of CYP 3A induction</measure>
    <time_frame>Day 1 and 9</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.
Single oral administration of dabigatran etexilate on Day 1;
Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;
Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;
Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>150 mg Dabigatran etexilate</description>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <other_name>Pradaxa®</other_name>
    <other_name>BIBR 1048 MS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>600 mg Rifampicin</description>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <other_name>Rifa® 600</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects according to the following criteria: based upon a
             complete medical history, including the physical examination, vital signs (BP, pulse
             rate), 12-lead ECG, clinical laboratory tests

          -  Age ≥18 and Age ≤45 years

          -  Body Mass Index (BMI) ≥18.5 and ≤29.9 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion Criteria:

          -  Any gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          -  Subjects who in the investigator's judgement were perceived as having an increased
             risk of bleeding, for example because of:

               -  Hemorrhagic disorders or bleeding diathesis

               -  Occult blood in faeces or haematocryal

               -  Trauma or surgery within the last month or as long as an excessive risk of
                  bleeding persisted after these events, or planned surgery during trial
                  participation

               -  History of arteriovenous malformation or aneurysm

               -  History of gastroduodenal ulcer disease, gastrointestinal haemorrhage, and
                  haemorrhoids

               -  History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic
                  intraarticular bleeding

               -  Use of drugs that may have interfered with haemostasis during trial conduct (e.g.
                  acetylic salicylic acid or other non-steroidal anti-inflammatory drugs)

               -  Relevant surgery of gastrointestinal tract

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which was deemed relevant
             to the trial as judged by the investigator

          -  Use of drugs which might have reasonably influenced the results of the trial based on
             the knowledge at the time of protocol preparation within four weeks prior to
             administration or during the trial, especially inhibitors or inducers of P-gp, CYP3A4,
             CYP2C9, or CYP2C19 trial (comment: CYP3A4 inhibitors are for example azole
             antimycotics, macrolides or grapefruit juice, CYP3A inducers are for example St.
             John's Wort or certain anticonvulsants)

          -  Intake of medication, which influences the blood clotting, i.e. acetylsalicylic acid,
             nonsteroidal anti-rheumatic drugs, cumarin, etc. within 14 days prior to screening or
             during the trial

          -  Participation in another trial with an investigational drug within one month prior to
             administration or during the trial

          -  Alcohol abuse (more than 60 g/day in males, more than 40 g/day in females)

          -  Drug abuse

          -  Blood donation (more than 100 mL within 4 weeks prior to administration)

          -  Any laboratory value outside the reference range that was of clinical relevance

          -  Inability to comply with dietary regimen of study centre

          -  Previous intake of rifampicin

          -  For female subjects:

               -  Pregnancy / positive pregnancy test, or planning to become pregnant during the
                  study or within 1 month of study completion

               -  No adequate contraception in women of childbearing potential

               -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

